ABOS Key Statistics, Chart & Performance
The current stock price of ABOS is 1.81 USD. In the past month the price decreased by -4.74%. In the past year, price increased by 9.7%.
ABOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About ABOS
Company Profile
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Newton, Massachusetts and currently employs 61 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The firm is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
Company Info
ACUMEN PHARMACEUTICALS INC
1210-1220 Washington Street, Suite 210
Newton MASSACHUSETTS US
CEO: Daniel O'Connell
Employees: 61
Phone: 16173444190
ACUMEN PHARMACEUTICALS INC / ABOS FAQ
What does ABOS do?
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Newton, Massachusetts and currently employs 61 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The firm is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
What is the stock price of ACUMEN PHARMACEUTICALS INC today?
The current stock price of ABOS is 1.81 USD. The price decreased by -2.69% in the last trading session.
Does ABOS stock pay dividends?
ABOS does not pay a dividend.
What is the ChartMill rating of ACUMEN PHARMACEUTICALS INC stock?
ABOS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the market capitalization of ABOS stock?
ACUMEN PHARMACEUTICALS INC (ABOS) has a market capitalization of 109.63M USD. This makes ABOS a Micro Cap stock.
Can you provide the upcoming earnings date for ACUMEN PHARMACEUTICALS INC?
ACUMEN PHARMACEUTICALS INC (ABOS) will report earnings on 2026-03-25, after the market close.
What is the Short Interest ratio of ACUMEN PHARMACEUTICALS INC (ABOS) stock?
The outstanding short interest for ACUMEN PHARMACEUTICALS INC (ABOS) is 1.01% of its float.
ABOS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ABOS. When comparing the yearly performance of all stocks, ABOS is a bad performer in the overall market: 72.85% of all stocks are doing better.
ABOS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABOS. Both the profitability and financial health of ABOS have multiple concerns.
ABOS Financial Highlights
Over the last trailing twelve months ABOS reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS decreased by -62.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.76% | ||
| ROE | -143.12% | ||
| Debt/Equity | 0.29 |
ABOS Forecast & Estimates
12 analysts have analysed ABOS and the average price target is 6.53 USD. This implies a price increase of 260.66% is expected in the next year compared to the current price of 1.81.